Coeck Nele, de Jong Bouke C, Diels Maren, de Rijk Pim, Ardizzoni Elisa, Van Deun Armand, Rigouts Leen
Mycobacteriology Unit, Institute of Tropical Medicine, Antwerp, Belgium Department of Biomedical Sciences, Antwerp University, Antwerp, Belgium.
Mycobacteriology Unit, Institute of Tropical Medicine, Antwerp, Belgium Department of Medicine, Division of Infectious Diseases, New York University, New York, USA Vaccinology Department, Medical Research Council Unit, Fajara, The Gambia.
J Antimicrob Chemother. 2016 May;71(5):1233-40. doi: 10.1093/jac/dkv499. Epub 2016 Feb 6.
Molecular resistance testing fails to explain all fluoroquinolone resistance, with a continued need for a suitable rapid phenotypic drug susceptibility testing method.
To evaluate the optimal method for phenotypic fluoroquinolone susceptibility testing.
Using Löwenstein-Jensen medium, Middlebrook 7H11 agar, BACTEC-MGIT 960 and the resazurin microtitre plate assay, we determined susceptibility to fluoroquinolones in Mycobacterium tuberculosis and investigated cross-resistance between ofloxacin, levofloxacin, moxifloxacin and gatifloxacin. We compared MICs of all four fluoroquinolones for 91 strains on Löwenstein-Jensen (as the gold standard) with their MICs in resazurin plates, and with ofloxacin susceptibility at a single concentration in MGIT and on 7H11 agar, in addition to sequencing of the gyrAB genes.
Applying a cut-off of 2 mg/L ofloxacin, 1 mg/L levofloxacin and 0.5 mg/L moxifloxacin and gatifloxacin in all methods, some discordance between solid medium and MGIT methods was observed, yet this tended to be explained by MICs around the cut-off. The high discordance between Löwenstein-Jensen (LJ) and resazurin plates suggests that the currently applied cut-offs for all fluoroquinolones in the resazurin method should decrease and minor changes in colour (from blue to purple) be considered as meaningful. High-level resistance in all assays to all drugs correlated well with the presence of gyrA mutations, in support of recent findings that fluoroquinolone resistance should be tested at different concentrations, as patients with lower levels of resistance may continue to benefit from high-dose fluoroquinolone-based therapy.
分子耐药性检测无法解释所有氟喹诺酮类药物耐药情况,因此持续需要一种合适的快速表型药物敏感性检测方法。
评估表型氟喹诺酮类药物敏感性检测的最佳方法。
使用罗氏培养基、Middlebrook 7H11琼脂、BACTEC-MGIT 960和刃天青微量滴定板法,我们测定了结核分枝杆菌对氟喹诺酮类药物的敏感性,并研究了氧氟沙星、左氧氟沙星、莫西沙星和加替沙星之间的交叉耐药性。我们将91株菌株在罗氏培养基(作为金标准)上对所有四种氟喹诺酮类药物的最低抑菌浓度(MIC)与它们在刃天青平板中的MIC进行比较,并与在MGIT和7H11琼脂上单一浓度的氧氟沙星敏感性进行比较,此外还对gyrAB基因进行了测序。
在所有方法中,将氧氟沙星的临界值设定为2mg/L,左氧氟沙星为1mg/L以及莫西沙星和加替沙星为0.5mg/L时,在固体培养基和MGIT方法之间观察到了一些不一致性,但这往往可以通过临界值附近的MIC来解释。罗氏培养基(LJ)和刃天青平板之间的高度不一致表明,目前在刃天青法中应用的所有氟喹诺酮类药物的临界值应该降低,并且颜色的微小变化(从蓝色到紫色)应被视为有意义的。在所有检测中,所有药物的高水平耐药与gyrA突变的存在密切相关,这支持了最近的研究结果,即氟喹诺酮类药物耐药性应在不同浓度下进行检测,因为耐药水平较低的患者可能继续从高剂量氟喹诺酮类药物治疗中获益。